Vasa Therapeutics is a San Diego-based, private biotechnology company committed to the discovery and development of therapeutics that target pathophysiology of cardiovascular aging. Vasa Therapeutics has three active preclinical programs: 1. VS-041 is the first personalized medicine-based treatment of HFpEF. VS-041 shows robust reduction of cardiac fibrosis in a preclinical HFpEF model and inhibits release of signaling collagen fragments, such as PRO-C6, that mediate fibroinflammatory responses and are biomarkers of worse outcomes in HFpEF patients. Phase 1 clinical trial of VS-041 is planned for 2024. 2. Long acting apelin peptide analogs for combination treatment with incretins in obesity patients at risk for skeletal muscle loss or cardiovascular disease. As a monotherapy, long acting apelin agonists could also be beneficial in muscle atrophy, heart failure, chronic kidney disease, and peripheral artery disease. 3. A best-in-class inhibitor of CamKIId for heart failure and life-threatening arrhythmias.